Advertisement
BSX vs ISRG
Which Stock Would AI Choose? Boston Scientific (BSX) vs. Intuitive Surgical (ISRG) Stock Comparison
Key Takeaways
- Both BSX and ISRG are leading medical technology companies that have experienced substantial stock price corrections in 2026 amid broader sector pressures and company-specific growth concerns.
- BSX reported solid first-quarter 2026 results with 11.6% revenue growth but subsequently lowered full-year guidance, contributing to recent volatility and multiple analyst target reductions.
- ISRG delivered a second-quarter 2026 revenue beat with 18.5% year-over-year growth yet faced post-earnings selling pressure linked to slowing procedure volumes and a component recall.
- Recent market activity shows both stocks trading well below 2025 highs, with BSX near $44 and ISRG near $338 as of late July 2026, reflecting compressed valuations relative to prior peaks.
- Business models differ markedly: BSX offers diversified cardiovascular and endoscopy exposure, while ISRG maintains a concentrated position in robotic-assisted surgery systems.
- Market sentiment has shifted toward caution for both names, with relative performance influenced by earnings visibility, competitive dynamics, and macroeconomic factors affecting healthcare capital spending.
Introduction
Medical device stocks BSX and ISRG operate in overlapping healthcare innovation spaces yet follow distinct paths. Boston Scientific Corporation develops and markets a broad portfolio of devices focused on cardiovascular, rhythm management, and endoscopy applications. Intuitive Surgical, Inc. specializes in robotic surgical systems that enable minimally invasive procedures. Investors and traders seeking exposure to medtech growth often compare the two for differences in revenue diversification, procedure-driven demand, valuation multiples, and sensitivity to hospital capital budgets. This analysis examines recent performance, business fundamentals, and positioning to assist those evaluating relative opportunities in the current environment.
BSX Overview and Recent Performance
Boston Scientific Corporation (NYSE: BSX) generates revenue across multiple therapeutic areas, including interventional cardiology, peripheral interventions, and structural heart solutions. In the first quarter of 2026, the company reported net sales of $5.203 billion, reflecting 11.6% reported growth and 9.4% organic growth, alongside adjusted earnings per share (EPS) of $0.80. Despite the solid quarter, management revised full-year 2026 organic sales growth guidance downward to a 6.5%–8.0% range. Recent market activity has featured notable volatility, with the stock declining sharply from 2025 peaks and trading near $44.25 as of July 24, 2026. Factors influencing sentiment include analyst target reductions, concerns over specific product segments such as WATCHMAN, and upcoming second-quarter earnings scheduled for July 29. The pullback has compressed valuation multiples while highlighting the company’s diversified revenue base as a potential buffer against single-product volatility.
ISRG Overview and Recent Performance
Intuitive Surgical, Inc. (NASDAQ: ISRG) designs and manufactures robotic systems, primarily the da Vinci platform, along with related instruments and accessories that drive recurring revenue through procedure volumes. Second-quarter 2026 results showed revenue of $2.89 billion, an 18.5% year-over-year increase that exceeded consensus estimates, with adjusted EPS of $2.80 also beating expectations. However, the stock reacted negatively to the report, declining approximately 7% intraday amid commentary on moderating global procedure growth and a Class II recall affecting certain system components. As of late July 2026, shares traded near $337–$340, well below the January 2025 high above $600. Recent performance reflects positioning ahead of and reaction to earnings, alongside broader caution on elective surgery volumes and capital equipment spending by hospitals. The company’s high-margin, procedure-centric model continues to underpin long-term investor interest despite near-term headwinds.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of the platform’s most suitable AI trading bots for prevailing market conditions. Tickeron offers hundreds of AI trading bots that can trade thousands of different tickers, yet only those demonstrating the strongest alignment with current trends, risk parameters, and performance metrics earn placement in this curated section. Available bots span a wide range of trading styles, strategies, timeframes, and statistical profiles, allowing users to match bots to specific tickers such as BSX or ISRG based on historical win rates, drawdown controls, and signal frequency. This dynamic filtering helps traders identify bots with robust recent track records without requiring manual optimization across the entire library. Explore the full selection on the Trending AI Robots page to review detailed statistics and suitability for individual strategies.
Head-to-Head Comparison
The two companies differ significantly in business model and growth profile. BSX maintains a diversified portfolio that reduces reliance on any single product line, supporting more stable but moderate revenue expansion. In contrast, ISRG derives a large portion of revenue from high-margin recurring instrument sales tied directly to da Vinci procedure volumes, creating greater operating leverage but also heightened sensitivity to utilization trends. Recent momentum has favored neither name decisively; both have posted substantial drawdowns in 2026, though ISRG retains a larger absolute price level and historically higher valuation multiples. Risk factors for BSX include integration of recent acquisitions and segment-specific slowdowns, while ISRG faces potential competition in robotics and recall-related overhang. Sector exposure is similar—both benefit from aging populations and minimally invasive procedure adoption—yet market sentiment currently prices in more near-term uncertainty for the diversified player amid guidance adjustments.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings visibility, and relative positioning, Tickeron’s AI framework would currently assign a probabilistic preference to ISRG over BSX in the near term. ISRG’s core procedural growth trajectory remains in double-digit territory despite recent moderation, offering clearer trend signals for momentum-oriented models. BSX’s simultaneous guidance reset and multiple analyst adjustments introduce additional variables that trend-following approaches typically weigh more conservatively. The assessment remains probabilistic rather than absolute, as compressed valuations at BSX could support mean-reversion potential if near-term catalysts stabilize.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSX is a Buy and ISRG is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BSX’s FA Score shows that 0 FA rating(s) are green whileISRG’s FA Score has 0 green FA rating(s).
- BSX’s FA Score: 0 green, 5 red.
- ISRG’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BSX’s TA Score shows that 5 TA indicator(s) are bullish while ISRG’s TA Score has 7 bullish TA indicator(s).
- BSX’s TA Score: 5 bullish, 4 bearish.
- ISRG’s TA Score: 7 bullish, 2 bearish.
Price Growth
BSX (@Medical/Nursing Services) experienced а +7.71% price change this week, while ISRG (@Pharmaceuticals: Other) price change was +6.95% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.21%. For the same industry, the average monthly price growth was +0.58%, and the average quarterly price growth was -4.36%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.91%. For the same industry, the average monthly price growth was +7.38%, and the average quarterly price growth was +6.28%.
Reported Earning Dates
BSX is expected to report earnings on Oct 28, 2026.
ISRG is expected to report earnings on Oct 20, 2026.
Industries' Descriptions
@Medical/Nursing Services (+2.21% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+2.91% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BSX | ISRG | BSX / ISRG | |
| Capitalization | 74.5B | 142B | 52% |
| EBITDA | 5.49B | 4.25B | 129% |
| Gain YTD | -46.072 | -29.149 | 158% |
| P/E Ratio | 20.82 | 46.02 | 45% |
| Revenue | 20.6B | 11B | 187% |
| Total Cash | 1.45B | 5.22B | 28% |
| Total Debt | 11B | 87M | 12,644% |
BSX | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 29 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 90 | 82 | |
SMR RATING 1..100 | 58 | 51 | |
PRICE GROWTH RATING 1..100 | 62 | 62 | |
P/E GROWTH RATING 1..100 | 98 | 83 | |
SEASONALITY SCORE 1..100 | n/a | 46 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BSX's Valuation (69) in the Medical Specialties industry is in the same range as ISRG (74). This means that BSX’s stock grew similarly to ISRG’s over the last 12 months.
ISRG's Profit vs Risk Rating (82) in the Medical Specialties industry is in the same range as BSX (90). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is in the same range as BSX (58). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
ISRG's Price Growth Rating (62) in the Medical Specialties industry is in the same range as BSX (62). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
ISRG's P/E Growth Rating (83) in the Medical Specialties industry is in the same range as BSX (98). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
| BSX | ISRG | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 26% | 1 day ago 63% |
| Stochastic ODDS (%) | 1 day ago 42% | 1 day ago 57% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 75% |
| MACD ODDS (%) | N/A | 1 day ago 58% |
| TrendWeek ODDS (%) | 1 day ago 55% | 1 day ago 63% |
| TrendMonth ODDS (%) | 1 day ago 55% | 1 day ago 70% |
| Advances ODDS (%) | 1 day ago 58% | 1 day ago 66% |
| Declines ODDS (%) | 15 days ago 55% | 15 days ago 61% |
| BollingerBands ODDS (%) | 1 day ago 45% | 1 day ago 65% |
| Aroon ODDS (%) | 1 day ago 54% | 7 days ago 73% |
Advertisement
BSX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BSX has been closely correlated with ISRG. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSX jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To BSX | 1D Price Change % | ||
|---|---|---|---|---|
| BSX | 100% | +0.45% | ||
| ISRG - BSX | 71% Closely correlated | +0.01% | ||
| MMSI - BSX | 56% Loosely correlated | +0.10% | ||
| ALC - BSX | 49% Loosely correlated | -2.35% | ||
| NTRA - BSX | 45% Loosely correlated | +1.04% | ||
| MDT - BSX | 45% Loosely correlated | +0.09% | ||
More | ||||
ISRG and
Correlation & Price change
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | +0.01% | ||
| BSX - ISRG | 73% Closely correlated | +0.45% | ||
| SYK - ISRG | 64% Loosely correlated | -0.27% | ||
| NTRA - ISRG | 54% Loosely correlated | +1.04% | ||
| GKOS - ISRG | 51% Loosely correlated | +2.54% | ||
| PODD - ISRG | 49% Loosely correlated | +0.25% | ||
More | ||||